Rhodes Jason P
Director at DYN; Director at Generation Bio Co.; Director at REPL, and 1 more
- Sold, on record
- $216M
- Dollars the filings state
- Form 4 sales
- 32
- Latest Aug 14, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- DYNDyne Therapeutics, Inc.Director
- Generation Bio Co.Director
- REPLReplimune Group, Inc.Director
- Epizyme, Inc.President, CFO and Treasurer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- DYN7.6M shares
- Generation Bio Co.699,949 shares
- REPL395,954 shares
- Epizyme, Inc.235,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale DYNRoutineApr 22 2026
Sold 834,302 shares at $19.75 ($16.5M)
Rhodes Jason P, Director
10b5-1 planSold 39.4% of holdings ($41.9M position)1.3M shares leftFiling
- 2 Form 4 sale DYNRoutineApr 27 +5 days
Sold 384,549 shares at $18.47 ($7.1M)
Rhodes Jason P, Director
10b5-1 planSold 24.2% of holdings ($29.4M position)1.2M shares leftFiling
- 3 Form 4 sale DYNRoutineApr 28 +1 day
Sold 227,337 shares at $18.38 ($4.2M)
Rhodes Jason P, Director
10b5-1 planSold 16.4% of holdings ($25.5M position)1.2M shares left0.6x usual sizeFiling
- 4 Form 4 sale DYNRoutineMay 6 +8 days
Sold 106,723 shares at $18.14 ($1.9M)
Rhodes Jason P, Director
10b5-1 planSold 8.6% of holdings ($22.6M position)1.1M shares left0.3x usual sizeFiling
- 5 Form 4 sale DYNRoutineJun 25 +50 days
Sold 267,760 shares at $21.09 ($5.6M)
Rhodes Jason P, Director
10b5-1 planSold 19.9% of holdings ($28.4M position)1.1M shares left1.2x usual sizeFiling
- 6 Form 4 sale DYNRoutineJun 29 +4 days
Sold 504,695 shares at $21.23 ($10.7M)
Rhodes Jason P, Director
10b5-1 planSold 34.1% of holdings ($31.4M position)975,931 shares left2x usual sizeFiling
- 7 Form 4 sale DYNRoutineJul 7 +8 days
Sold 777,451 shares at $22.97 ($17.9M)
Rhodes Jason P, Director
10b5-1 planSold 99.6% of holdings ($17.9M position)2,962 shares left2.9x usual sizeFiling
- 8 Form 4 sale DYNUnusualAug 14 +38 days
Sold 2.6M shares at $25.20 ($65.2M)
Rhodes Jason P, Director
10b5-1 planSold 85.8% of holdings ($76M position)428,946 shares left7.9x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (32)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | DYN | Director | Form 4 sale | 2.6M | $65.2M | 85.8% | Unusual | SEC |
| Jul 7, 2026 | DYN | Director | Form 4 sale | 777,451 | $17.9M | 99.6% | Routine | SEC |
| Jun 29, 2026 | DYN | Director | Form 4 sale | 504,695 | $10.7M | 34.1% | Routine | SEC |
| Jun 25, 2026 | DYN | Director | Form 4 sale | 267,760 | $5.6M | 19.9% | Routine | SEC |
| May 6, 2026 | DYN | Director | Form 4 sale | 106,723 | $1.9M | 8.6% | Routine | SEC |
| Apr 28, 2026 | DYN | Director | Form 4 sale | 227,337 | $4.2M | 16.4% | Routine | SEC |
| Apr 27, 2026 | DYN | Director | Form 4 sale | 384,549 | $7.1M | 24.2% | Routine | SEC |
| Apr 22, 2026 | DYN | Director | Form 4 sale | 834,302 | $16.5M | 39.4% | Routine | SEC |
| Nov 14, 2024 | DYN | Director | Form 4 sale | 782 | $26k | 0.1% | No plan | SEC |
| Mar 1, 2024 | DYN | Director | Form 4 sale | 46,534 | $1.4M | 5.2% | Routine | SEC |
| Feb 28, 2024 | DYN | Director | Form 4 sale | 807,838 | $19.6M | 48.3% | Routine | SEC |
| Feb 23, 2024 | DYN | Director | Form 4 sale | 500,789 | $11.3M | 35.2% | Routine | SEC |
| Feb 20, 2024 | DYN | Director | Form 4 sale | 510,152 | $11.9M | 7.0% | Routine | SEC |
| Sep 29, 2021 | Generation Bio Co. | Director | Form 4 sale | 81,088 | $2.1M | 99.3% | Unusual | SEC |
| Sep 24, 2021 | Generation Bio Co. | Director | Form 4 sale | 134,998 | $3.5M | 99.4% | Unusual | SEC |
| Jun 24, 2021 | Generation Bio Co. | Director | Form 4 sale | 31,008 | $802k | 98.1% | Unusual | SEC |
| Jun 23, 2021 | Generation Bio Co. | Director | Form 4 sale | 185,078 | $4.6M | 99.6% | Unusual | SEC |
| Apr 14, 2021 | Generation Bio Co. | Director | Form 4 sale | 140,682 | $3.6M | 100.0% | Unusual | SEC |
| Apr 9, 2021 | Generation Bio Co. | Director | Form 4 sale | 127,095 | $3.6M | 47.5% | Unusual | SEC |
| Jan 26, 2021 | REPL | Director | Form 4 sale | 5,558 | $256k | 0.6% | Plan not stated | SEC |
| Dec 18, 2020 | REPL | Director | Form 4 sale | 4,319 | $181k | 18.3% | Plan not stated | SEC |
| Dec 17, 2020 | REPL | Director | Form 4 sale | 65,029 | $2.7M | 76.9% | Unusual | SEC |
| Dec 14, 2020 | REPL | Director | Form 4 sale | 103,686 | $4.5M | 81.5% | Unusual | SEC |
| Dec 9, 2020 | REPL | Director | Form 4 sale | 217,362 | $10M | 88.0% | Unusual | SEC |
| Sep 2, 2014 | Epizyme, Inc. | President, CFO and Treasurer | Form 4 sale | 30,000 | $1M | 24.2% | Plan not stated | SEC |
| Aug 4, 2014 | Epizyme, Inc. | President, CFO and Treasurer | Form 4 sale | 30,000 | $892k | 26.8% | Unusual | SEC |
| Jul 7, 2014 | Epizyme, Inc. | President, CFO and Treasurer | Form 4 sale | 30,000 | $982k | 30.0% | Unusual | SEC |
| Jun 2, 2014 | Epizyme, Inc. | President, CFO and Treasurer | Form 4 sale | 30,000 | $666k | 34.1% | Unusual | SEC |
| May 5, 2014 | Epizyme, Inc. | President, CFO and Treasurer | Form 4 sale | 30,000 | $646k | 39.5% | Unusual | SEC |
| Apr 7, 2014 | Epizyme, Inc. | President, CFO and Treasurer | Form 4 sale | 25,000 | $501k | 42.4% | Unusual | SEC |
| Feb 10, 2014 | Epizyme, Inc. | President, CFO and Treasurer | Form 4 sale | 50,000 | $1.5M | 67.6% | Unusual | SEC |
| Jan 6, 2014 | Epizyme, Inc. | President, CFO and Treasurer | Form 4 sale | 10,000 | $202k | 71.4% | Unusual | SEC |